Mark Chin, Director at Iterum Therapeutics plc (ITRM), bought 58,000 shares at $6.10 ($354K) on 2018-10-30, disclosed to the SEC on 2018-11-01.
Open-market purchase of $354k ITRM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| IMRA | BUY | 2021-07-28 | $8.0M | — | Filing → |
| IMRA | BUY | 2020-03-16 | $3.0M | — | Filing → |
| HARP | SELL | 2019-12-17 | $1.2M | — | Filing → |